From Fitch Ratings
Glenmark Pharmaceuticals announced that Fitch Ratings has reaffirmed the Company's Long-Term Issuer Default Rating (IDR) at 'BB'. The Outlook is Stable. The agency also affirmed the rating on Glenmark's USD200 million 4.50% senior unsecured notes due 2021 at 'BB'. The notes are rated at the same level as the IDR because they constitute Glenmark's direct and senior unsecured obligations.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
